A decade ago researchers announced development of a cancer immunotherapy called CAR (for chimeric antigen receptor)-T, in which a patient is re-infused with their own genetically modified T cells equipped to mount a potent anti-tumor attack. Since then CAR T approaches (one of several strategies collectively known as 'adoptive T cell transfer') have made headlines as a novel cellular immunotherapy tool, most successfully against so-called 'liquid cancers' like leukemias and lymphomas.
from EurekAlert! - Breaking News http://bit.ly/2ECOG83
via IFTTT
Tuesday, May 28, 2019
De-TOXing exhausted T cells may bolster CAR T immunotherapy against solid tumors
About Admin -
Author Description here.. Nulla sagittis convallis. Curabitur consequat. Quisque metus enim, venenatis fermentum, mollis in, porta et, nibh. Duis vulputate elit in elit. Mauris dictum libero id justo.